Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $113.69 +2.78 (+2.51%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$110.03▼$113.8350-Day Range$110.31▼$131.9152-Week Range$74.75▼$142.00Volume1.35 million shsAverage Volume2.92 million shsMarket Capitalization$45.21 billionP/E Ratio73.35Dividend YieldN/APrice Target$140.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DexCom alerts: Email Address DexCom MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside23.4% Upside$140.33 Price TargetShort InterestHealthy2.27% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment1.13Based on 6 Articles This WeekInsider TradingSelling Shares$7.62 M Sold Last QuarterProj. Earnings Growth25.28%From $1.78 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector65th out of 879 stocksSurgical & Medical Instruments Industry10th out of 95 stocks 2.4 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has only been the subject of 4 research reports in the past 90 days.Read more about DexCom's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.27% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently increased by 3.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 2.8 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for DexCom this week, compared to 12 articles on an average week.Search InterestOnly 12 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,619,347.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 25.28% in the coming year, from $1.78 to $2.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 73.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.10.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 73.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.85.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 21.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About DexCom Stock (NASDAQ:DXCM)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More DXCM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Stock News HeadlinesJune 29, 2024 | insidertrades.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 659 Shares of StockJune 19, 2024 | insidertrades.comInsider Selling: DexCom, Inc. (NASDAQ:DXCM) Director Sells 1,000 Shares of StockJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 12, 2024 | insidertrades.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $49,126.35 in StockJuly 4, 2024 | fool.com2 Top Growth Stocks to Buy With $1,000July 3, 2024 | seekingalpha.comDexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still IntactJune 30, 2024 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) EVP Sells $75,317.11 in StockJune 28, 2024 | insidermonkey.comWhy Is DexCom, Inc. (DXCM) One Of The Best Growth Stocks for Billionaire Ray Dalio?July 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 21, 2024 | investorplace.comHype Hazards: 3 Stocks to Steer Clear of on Your Wealth-Building JourneyJune 20, 2024 | businesswire.comDexcom Expands AID Partnership Into The NetherlandsJune 20, 2024 | businesswire.comDexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 DiabetesJune 19, 2024 | investorplace.comThe 3 Best Diabetes Stocks to Buy in June 2024June 5, 2024 | businesswire.comDexcom G7 Now Connects Directly to Apple Watch in the U.S.June 4, 2024 | businesswire.comDexcom Wins Access to Dexcom One for 100,000 People Living With Type 2 DiabetesJune 3, 2024 | fool.comBull Market Buys: 2 Growth Stocks to Own for the Long HaulMay 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024May 29, 2024 | investorplace.comThe 3 Best MedTech Stocks to Buy Now: May 2024See More Headlines Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today7/07/2024Next Earnings (Confirmed)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$140.33 High Stock Price Target$165.00 Low Stock Price Target$100.00 Potential Upside/Downside+23.4%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$1.55 Trailing P/E Ratio73.35 Forward P/E Ratio63.87 P/E Growth2.78Net Income$541.50 million Net Margins16.82% Pretax Margin20.48% Return on Equity31.01% Return on Assets10.29% Debt Debt-to-Equity Ratio1.08 Current Ratio2.90 Quick Ratio2.53 Sales & Book Value Annual Sales$3.62 billion Price / Sales12.48 Cash Flow$2.07 per share Price / Cash Flow54.94 Book Value$5.35 per share Price / Book21.25Miscellaneous Outstanding Shares397,680,000Free Float396,491,000Market Cap$45.21 billion OptionableOptionable Beta1.16 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Kevin Ronald Sayer (Age 66)Executive Chairman, CEO & President Comp: $3.23MMr. Jereme M. Sylvain (Age 44)Executive VP, CFO & Chief Accounting Officer Comp: $1.13MMr. Jacob Steven Leach (Age 46)Executive VP & COO Comp: $1.29MMr. Michael Jon Brown (Age 54)Executive VP & Chief Legal Officer Comp: $1.22MMs. Teri Lawver (Age 57)Executive VP & Chief Commercial Officer Comp: $1.41MMr. Girish Naganathan (Age 47)Executive VP & CTO Comp: $423.92kMr. Shelly Ramasamy Selvaraj (Age 65)Senior VP & Chief Information Officer Mr. Sean ChristensenDirector of Corporate Affairs & Head of Investor RelationsMr. Matthew Dolan (Age 43)Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne MarshExecutive Vice President of MarketingMore ExecutivesKey CompetitorsAbiomedNASDAQ:ABMDNovoCureNASDAQ:NVCRIntuitive SurgicalNASDAQ:ISRGStrykerNYSE:SYKBoston ScientificNYSE:BSXView All CompetitorsInsiders & InstitutionsDNB Asset Management ASBought 44,752 shares on 7/5/2024Ownership: 0.036%First Hawaiian BankSold 1,575 shares on 7/2/2024Ownership: 0.004%GAMMA Investing LLCBought 248 shares on 7/2/2024Ownership: 0.001%Massmutual Trust Co. FSB ADVBought 221 shares on 7/2/2024Ownership: 0.000%Cullen Investment Group LTD.Bought 562 shares on 7/1/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $124.09 at the start of the year. Since then, DXCM stock has decreased by 8.4% and is now trading at $113.69. View the best growth stocks for 2024 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Thursday, April, 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The medical device company had revenue of $921 million for the quarter, compared to analysts' expectations of $911.20 million. DexCom had a trailing twelve-month return on equity of 31.01% and a net margin of 16.82%. Read the conference call transcript. When did DexCom's stock split? DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. Does DexCom have any subsidiaries? DexCom subsidiaries include TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional investors include DNB Asset Management AS (0.04%), First Hawaiian Bank, Bank of New Hampshire and Cullen Investment Group LTD.. Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson, Andrew K Balo, Barbara Kahn, Richard Alexander Collins, Mark G Foletta, Sumi Shrishrimal, Patrick Michael Murphy and Nicholas Augustinos. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM) and ServiceNow (NOW). This page (NASDAQ:DXCM) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DXCM Stock Alerts